Welcome to our dedicated page for Stereotaxis news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis stock.
Stereotaxis, Inc. (STXS) is a global leader in innovative robotic technologies aimed at improving the treatment of arrhythmias and endovascular procedures. The company's mission focuses on the discovery, development, and delivery of advanced robotic systems, instruments, and information solutions tailored for the interventional laboratory. By leveraging cutting-edge innovations, Stereotaxis helps physicians provide superior patient care with robotic precision and safety, streamline lab efficiency, and enhance procedural information integration.
Stereotaxis boasts over 100 issued patents that form the backbone of its platform. The core components of its systems have received regulatory clearance in various regions including the United States, European Union, Japan, Canada, and China, among others. This broad regulatory approval underscores the global trust and reliance on Stereotaxis' technology.
The company's revenue streams are diversified across systems, disposables, royalties, and subleases, with a significant portion generated from disposables, services, and accessories. Notably, the majority of its revenue is derived from the United States.
Through continuous innovation and dedication to serving the medical community, Stereotaxis remains at the forefront of robotic medical technology, making significant strides in improving procedural outcomes and operational efficiencies in healthcare settings worldwide.
For the latest updates and more information, visit Stereotaxis.
Stereotaxis (NYSE: STXS) reported a 6% year-over-year revenue increase to $8.7 million for Q3 2020, attributed to the installation of its Genesis RMN® Systems in the US and Europe. The system revenue was $3.0 million, while recurring revenue decreased to $5.5 million from $6.3 million due to a 10% decline in procedure volumes linked to COVID-19 impacts. The company anticipates $10-20 million in Genesis system revenue for 2021 and plans initial commercialization of a new robotic catheter. Operating loss was $1.6 million, with a cash balance of $43.8 million as of September 30, 2020.
Stereotaxis (NYSE: STXS) announces the release of its third quarter financial results on November 9, 2020, before U.S. market opening. The company will also host a conference call at 10:00 a.m. ET to discuss the results and corporate developments. Investors can access the call by dialing 800-437-2398 (US/Canada) or 856-344-9206 (International) with the pass code 9232669. A replay will be available for one week after the call. Stereotaxis is a leader in robotic technologies for cardiac arrhythmia treatment.
Stereotaxis (STXS) announced the installation of the Genesis Robotic Magnetic Navigation (RMN) systems at Helsinki University Hospital and Banner - University Medicine Heart Institute, the world’s first implementations aimed at treating heart rhythm disorders. These advanced robotic systems enhance precision in cardiac ablation procedures, addressing the growing need for effective solutions for arrhythmias, which can lead to serious health risks. The technology is expected to provide a competitive edge for both institutions in patient care and education in the field.
Stereotaxis (NYSE: STXS) announced that Chairman and CEO David Fischel will speak at RAPS Convergence 2020, the largest annual gathering of healthcare regulatory professionals, on September 13, 2020. Fischel will discuss how regulatory professionals can enhance medical innovation and healthcare access through interoperability and open standards. He emphasized the critical role that regulatory experts play in advancing healthcare innovation. Stereotaxis is known for its robotic technologies that improve arrhythmia treatment. For more information, visit www.stereotaxis.com.
Stereotaxis (NYSE: STXS), a leader in robotic technologies for cardiac arrhythmia treatment, announced CEO David Fischel will present at three investor conferences in September 2020. The presentations include the LD Micro 500 on September 4, Cantor Fitzgerald Global Healthcare on September 15, and Lake Street Best Ideas Growth on September 17, where one-on-one meetings will be available. Fischel aims to share insights on Stereotaxis’ technology and growth strategy, underlining the company’s commitment to enhancing patient care.
Stereotaxis (NYSE: STXS) announced a significant publication in the Journal of the American College of Cardiology, highlighting a study on robotic technology for treating chronic thromboembolic pulmonary hypertension (CTEPH). The trial, involving 50 patients, demonstrated that robotic magnetic navigation enhanced outcomes, with pulmonary vascular resistance improving significantly (p=0.001) and an 86% reduction in heart failure-related hospitalizations (p=0.049) at 12 months. This advancement in robotic technology presents a promising new therapy for pulmonary hypertension, revealing its potential beyond arrhythmias.
Stereotaxis (STXS) reported a 21% decline in second-quarter revenue, totaling $5.3 million, primarily due to a 38% drop in procedure volumes amid COVID-19 challenges. Despite this setback, the company achieved notable milestones, including the installation of the first Genesis RMN® System and advancements in its robotically-navigated ablation catheter. Operating expenses decreased 13% to $6.2 million, demonstrating prudent management. As of June 30, 2020, Stereotaxis held a cash balance of $44 million, positioning it strongly for future growth.
Stereotaxis (NYSE: STXS) and Acutus Medical have successfully conducted the first integrated cardiac ablation procedure utilizing remote TeleRobotic Support. Dr. Gery Tomassoni performed the procedure at Baptist Health in Lexington, KY, combining Stereotaxis Robotic Magnetic Navigation and Acutus' AcQMap systems. This innovative integration enhances the accuracy of arrhythmia treatment through high-resolution imaging and robotic navigation. The TeleRobotic capabilities allow real-time support from experts, improving patient care while minimizing surgical risks.
Stereotaxis (STXS) announced it will release its financial results for Q2 2020 on August 6, 2020, prior to the U.S. market opening. A conference call will follow at 10:00 a.m. ET to discuss the results and corporate developments. Investors can access the call via phone or webcast. Stereotaxis specializes in robotic technologies for treating cardiac arrhythmias, and its systems are approved in several major markets including the U.S., EU, and Japan.
STEREOTAXIS (NYSE: STXS), a leader in robotic technologies for cardiac arrhythmias, announced a publication in the European Heart Journal showcasing its technology's effectiveness in treating a COVID-19 patient with ventricular tachycardia. The publication advocates for remote catheter ablation to reduce infection risks for healthcare staff. The case study involved a 68-year-old patient who recovered without recurrence of arrhythmia. CEO David Fischel emphasized the technology's safety and efficiency in complex procedures, highlighting its role in protecting medical professionals during the COVID-19 pandemic.
FAQ
What is the current stock price of Stereotaxis (STXS)?
What is the market cap of Stereotaxis (STXS)?
What does Stereotaxis, Inc. specialize in?
What is the mission of Stereotaxis, Inc.?
Where has Stereotaxis' technology received regulatory clearance?
What are the main revenue streams for Stereotaxis, Inc.?
Who are the key executives at Stereotaxis, Inc.?
How does Stereotaxis' technology benefit physicians?
How many patents does Stereotaxis hold?
What geographic region generates the majority of Stereotaxis' revenue?
What types of procedures are enhanced by Stereotaxis' technology?
Where can I find more information about Stereotaxis, Inc.?
